Results 121 to 130 of about 1,816 (199)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations

Clinical Ophthalmology, 2020
Alfredo Adán,1 Francisco Cabrera,2 Marta S Figueroa,3 Enrique Cervera,4 Francisco J Ascaso,5 Patricia Udaondo,6 Maximino Abraldes,7 Miguel Ángel Reyes,8 Marta Pazos,1 Bernardete Pessoa,9 Félix Armadá10 1Hospital Clínic ...
Adán A, Cabrera F, Figueroa MS, Cervera E, Ascaso FJ, Udaondo P, Abraldes M, Reyes MÁ, Pazos M, Pessoa B, Armadá F   +10 more
doaj  

Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies. [PDF]

Ophthalmol Ther, 2021
Ansari AS, Amir Z, Williams GS.
europepmc   +1 more source

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema

International Medical Case Reports Journal, 2018
P Singh,1 A Chedid,1 SK Deuchler,1 T Kohnen,2 M Müller,2 FH Koch1 1Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany; 2Ophthalmology University Eye Hospital, Frankfurt am Main, Germany Purpose: There are little or no ...
Singh P, Chedid A, Deuchler SK, Kohnen T, Müller M, Koch FH   +5 more
doaj  

Determining the relative cost effectiveness of the fluocinolone acetonide intravitreal implant [PDF]

Current Medical Research and Opinion, 2017
openaire   +2 more sources

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. [PDF]

Br J Ophthalmol, 2021
Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, Werts E.   +6 more
europepmc   +1 more source

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) [PDF]

, 2015

core   +1 more source

Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis [PDF]

, 2011
Corticosteroids have been the mainstay of uveitis therapy. When intraocular inflammation is unresponsive to steroids, or steroid related side effects become a concern, steroid-sparing medications may be administered which can be classified into ...
Abdekhodaie, Mohammad Jafar, Haghjou, Nahid, Soheilian, Masoud   +2 more
core   +2 more sources

Fluocinolone acetonide implant in diabetic macular edema: sustained benefits and effects of following prior therapy

International Journal of Retina and Vitreous
Purpose To (1) evaluate long-term real-world anatomical and functional outcomes after implantation of a sustained-release fluocinolone acetonide (FAc) implant in eyes with diabetic macular edema (DME) and (2) to assess the influence of prior anti ...
Philipp Necpal, Klemens P. Kaiser, Ron C. Kroener, Pankaj Singh   +3 more
doaj   +1 more source

Good syndrome and other causes of cytomegalovirus retinitis in HIV-negative patients—case report and comprehensive review of the literature [PDF]

, 2016

core   +1 more source

Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema – A Single Center Study

Clinical Ophthalmology
Ricardo Machado Soares,* Catarina Cunha Ferreira,* Joana da Silva Fernandes, Carolina Madeira, Luís MA Silva, Eduardo Saraiva, Lígia Ribeiro, Sofia Fonseca Department of Ophthalmology - Centro Hospitalar Vila Nova de Gaia e Espinho, Porto ...
Soares RM, Ferreira CC, Fernandes JDS, Madeira C, Silva LMA, Saraiva E, Ribeiro L, Fonseca S   +7 more
doaj